## Edgar Filing: IDEXX LABORATORIES INC /DE - Form 4

IDEXX LAI Form 4 May 05, 201	BORATORIES I	NC /DE	5					-			
•									OMB AF	PROVAL	
FORM	UNITED	STATES		RITIES A shington			ANGE CO	OMMISSION	OMB Number:	3235-0287	
Check th if no lon subject t Section Form 4 c Form 5	ger <b>STATEN</b> o <b>STATEN</b> 16. or	STATEMENT OF CHAN							Estimated a burden hour response		
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940											
(Print or Type	Responses)										
1. Name and Address of Reporting Person <u>*</u> END WILLIAM T			2. Issuer Name <b>and</b> Ticker or Trading Symbol IDEXX LABORATORIES INC /DE					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
			[IDXX	]				(Check	an applicable	)	
			3. Date of Earliest Transaction (Month/Day/Year) 05/03/2016				- - 1	_X_ Director 10% Owner Officer (give title Other (specify below) below)			
			4. If Amendment, Date Original Filed(Month/Day/Year)				1	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
WESTBROOK, ME 04092 — Form filed by More than One Reporting Person											
(City)	(State)	(Zip)	Tab	le I - Non-	Derivativ	e Secu	rities Acqu	ired, Disposed of,	or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deen Executior any (Month/D	n Date, if Transactionor Disposed of (D) Code (Instr. 3, 4 and 5) Day/Year) (Instr. 8)			(D)	) 5. Amount of Securities Beneficially Owned Following Reported	OwnershipInForm:EDirect (D)C	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
_				Code V	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)	(Instr. 4)		
Common Stock	05/03/2016			М	9,924	А	\$ 26.655	63,578	D		
Common Stock	05/05/2016			S	4,924	D	\$ 85.8703 (1)	58,654	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

## Edgar Filing: IDEXX LABORATORIES INC /DE - Form 4

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amour or Numbe of Shares
Non-Qualified Stock Option (right-to-buy)	\$ 26.655	05/03/2016		М	9,924	(2)	02/13/2017	Common Stock	9,92

## **Reporting Owners**

Reporting Owner Name / Address		Relationsh							
	Director	10% Owner	Officer	Other					
END WILLIAM T ONE IDEXX DRIVE WESTBROOK, ME 04092	Х								
Signatures									
/s/ Lily J. Lu, Attorney-in-Fact T. End	for Willi	am	05/0	5/2016					
<u>**</u> Signature of Reporting Pe	rson		Ι	Date					
Explanation of Responses:									
* If the form is filed by more than one reporting person, <i>see</i> Instruction 4(b)(v).									

- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from (1) \$85.8510 to \$85.8906 inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.

Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4.962 shares on February 14, 2011, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the

- (2) "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- (3) Not applicable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.